Pharma firm SIGA Q2 product revenues rise

Reuters

Aug 06

Pharma firm SIGA <a href="https://laohu8.com/S/QTWO">Q2</a> product revenues rise

Overview

SIGA Q2 product revenues rise to $79 mln, driven by TPOXX sales
Company awarded $27 mln in BARDA 19C contract funding for development
Net income for Q2 jumps to $35.5 mln, reflecting strong performance

Result Drivers

TPOXX SALES - $53 mln from oral TPOXX and $26 mln from IV TPOXX sales to Strategic National Stockpile
BARDA FUNDING - $27 mln awarded for TPOXX pediatric program and manufacturing support under BARDA 19C contract

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 EPS		$0.49
Q2 Net Income		$35.50 mln

Analyst Coverage

The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release: ID:nGNX7jGW8k

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557521311"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557521311\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557521311?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 04:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557521311","market":"us","top_or_hot":-1,"title":"Pharma firm SIGA Q2 product revenues rise","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Pharma firm SIGA <a href=\"https://laohu8.com/S/QTWO\">Q2</a> product revenues rise</title></head><body>Overview<ul><li>SIGA Q2 product revenues rise to $79 mln, driven by TPOXX sales</li><li>Company awarded $27 mln in BARDA 19C contract funding for development</li><li>Net income for Q2 jumps to $35.5 mln, reflecting strong performance</li></ul>Result Drivers<ul><li>TPOXX SALES - $53 mln from oral TPOXX and $26 mln from IV TPOXX sales to Strategic National Stockpile</li><li>BARDA FUNDING - $27 mln awarded for TPOXX pediatric program and manufacturing support under BARDA 19C contract</li></ul>Key Details<table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q2 EPS</td><td></td><td>$0.49</td><td></td></tr><tr><td>Q2 Net Income</td><td></td><td>$35.50 mln</td><td></td></tr></tbody></table>Analyst Coverage<ul><li>The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 5 three months ago</li></ul>Press Release: ID:nGNX7jGW8k(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharma firm SIGA Q2 product revenues rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharma firm SIGA Q2 product revenues rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2025-08-06 04:09\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Pharma firm SIGA <a href=\"https://laohu8.com/S/QTWO\">Q2</a> product revenues rise</title></head><body>Overview<ul><li>SIGA Q2 product revenues rise to $79 mln, driven by TPOXX sales</li><li>Company awarded $27 mln in BARDA 19C contract funding for development</li><li>Net income for Q2 jumps to $35.5 mln, reflecting strong performance</li></ul>Result Drivers<ul><li>TPOXX SALES - $53 mln from oral TPOXX and $26 mln from IV TPOXX sales to Strategic National Stockpile</li><li>BARDA FUNDING - $27 mln awarded for TPOXX pediatric program and manufacturing support under BARDA 19C contract</li></ul>Key Details<table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q2 EPS</td><td></td><td>$0.49</td><td></td></tr><tr><td>Q2 Net Income</td><td></td><td>$35.50 mln</td><td></td></tr></tbody></table>Analyst Coverage<ul><li>The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 5 three months ago</li></ul>Press Release: ID:nGNX7jGW8k(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SIGA","symbol_name":"SIGA Technologies Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nPLXEB6044:1","article_id":"2557521311","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557521311","pubTimestamp":1754424594,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pharma firm SIGA Q2 product revenues riseOverviewSIGA Q2 product revenues rise to $79 mln, driven by TPOXX salesCompany awarded $27 mln in BARDA 19C contract funding for developmentNet income for Q2 j","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SIGA":"SIGA Technologies Inc","CMI":"康明斯"},"translate_title":"制药公司SIGA第二季度产品收入增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMI":0.9,"SIGA":0.9},"content_text":"Pharma firm SIGA Q2 product revenues riseOverviewSIGA Q2 product revenues rise to $79 mln, driven by TPOXX salesCompany awarded $27 mln in BARDA 19C contract funding for developmentNet income for Q2 jumps to $35.5 mln, reflecting strong performanceResult DriversTPOXX SALES - $53 mln from oral TPOXX and $26 mln from IV TPOXX sales to Strategic National StockpileBARDA FUNDING - $27 mln awarded for TPOXX pediatric program and manufacturing support under BARDA 19C contractKey DetailsMetricBeat/MissActualConsensus EstimateQ2 EPS$0.49Q2 Net Income$35.50 mlnAnalyst CoverageThe stock recently traded at 6 times the next 12-month earnings vs. a P/E of 5 three months agoPress Release: ID:nGNX7jGW8k(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}